BioCentury | Feb 9, 2018
Product R&D

R is for readout

...one polyclonal antibody. Among those, all but one antisense compound -- the Phase I/II-stage IONIS-STAT3Rx (AZD9150...
BioCentury | Feb 7, 2018
Distillery Techniques

Drug delivery

...as delivery vehicles for other therapeutic siRNAs. Ionis Pharmaceuticals Inc. and AstraZeneca plc have IONIS-STAT3RX (AZD9150...
BioCentury | May 12, 2016
Distillery Therapeutics

Therapeutics: MicroRNA-551b (miR-551b); signal transducer and activator of transcription 3 (STAT3)

...in models of serous ovarian cancer. Ionis Pharmaceuticals Inc. and AstraZeneca plc have AZD9150 ( IONIS-STAT3RX...
BioCentury | Aug 10, 2015
Strategy

Isis executes

...That deal also gave AZ rights to two Isis antisense programs in cancer. ISIS-STAT3-2.5Rx ( AZD9150...
BioCentury | Nov 24, 2014
Company News

Isis Pharmaceuticals, AstraZeneca deal

...against four undisclosed cancer targets from AZ. The payment was triggered by the advancement of ISIS-STAT3Rx...
BioCentury | Nov 17, 2014
Company News

Isis Pharmaceuticals, AstraZeneca deal

...the four previously partnered oligonucleotides including AZD9150 ( ISIS-STAT3Rx ) and AZD5312 ( ISIS-ARRx ). AZD9150...
...terms. Under a related 2012 deal, Isis granted AstraZeneca exclusive rights to develop and commercialize ISIS-STAT3Rx...
BioCentury | Nov 14, 2014
Top Story

AstraZeneca, Isis team up on antisense delivery

...AstraZeneca also gained exclusive rights to develop and commercialize two compounds from Isis: AZD9150 ( ISIS-STAT3Rx...
...delivery systems that can be applied to AZD9150 and AZD5312 as well as other oligonucleotides. AZD9150...
BioCentury | Jul 17, 2014
Distillery Therapeutics

Indication: Cancer

...targeting CTLA-4 in Phase II or earlier testing. Isis Pharmaceuticals Inc. and AstraZeneca plc have ISIS-STAT3Rx...
BioCentury | Jul 10, 2014
Distillery Therapeutics

Indication: Cancer

...leukemia, lymphoma and other cancer cell lines. Isis Pharmaceuticals Inc. and AstraZeneca plc have ISIS-STAT3Rx (AZD9150...
BioCentury | Jun 9, 2014
Emerging Company Profile

Glactone: ProSTATe stopper

...in CRPC, according to Johansson. The most advanced STAT3 compound for cancer is AZD9150 ( ISIS-STAT3Rx...
...cancer indications not including CRPC. Oral availability is a principal advantage of galiellalactone derivatives over AZD9150...
...administered by intravenous injection in solid tumor trials. Glactone's compounds also might have better tolerability. AZD9150...
Items per page:
1 - 10 of 24